Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

keratitis

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

- PMLiVE

NICE and ABPI clash over access to medicines

Trade body says research shows medicines underused but NICE claims new figures 'higher than expected'

- PMLiVE

NICE stroke guidance boost for Boehringer’s Actilyse

Institute changes guidance on alteplase use

- PMLiVE

Patient access schemes likely to remain under VBP, says NICE

New and existing schemes expected to have place within UK’s new pricing environment

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

UK reaffirms NHS access to NICE-approved drugs

Health Secretary makes pledge on same day Future Forum recommendations on NHS reform accepted

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links